CS Paper Radar

Reasoning in the loop: antibody lead optimization by probing mechanism and measurement

Samuel Stanton, Aaron Solomon, Emily Delaney, Melanie Montgomery, Crystal Humphries, Timothy Acker, Ryan Henrici, Charbel Eid, Eddie Abrams, Peyton Greenside

cs.LG cs.AIq-bio.BM ·submitted 2026-11-15 05:55 UTC · v1

Abstract

Lab-in-the-loop systems, in which a model proposes molecules, automated assays measure their properties and the results retrain the model, are a popular approach to antibody lead optimization. These systems optimize for a specification defined with metrics computed from instrument signals, so their success depends on how well those metrics serve as proxies for the properties a drug candidate needs. When a metric is a poor proxy, neither a better model nor more data will fix it, and identifying the problem usually requires expert review. We report two campaigns run on BigHat Biosciences' Milliner platform, one on an anti-albumin nanobody (VHH) and one on an anti-mesothelin single-chain variable fragment (scFv), in which a research team and a general-purpose AI agent, Claude, brought scientific reasoning into the loop. Over seven rounds and about 1,010 design variants we built libraries from antibody lineage, structure and biophysics, and found from the raw curves that on each scaffold one thermal metric did not measure what its name implied. The libraries were built as controlled comparisons, so the results also show what each mutation contributes to each property. We fit a physical model of the curves, used it to choose metrics suited to each scaffold, and changed the experimental protocol, varying protein concentration and heating rate, to test the model against pre-registered predictions. Both leads improve on their parents in affinity, thermal stability and aggregation while improving or maintaining yield and purity.

Comment
31 pages, 19 figures, 8 tables

Closest papers

Nearest neighbours by meaning across the whole index.

Can agents reliably design therapeutic antibodies?

cs.LG q-bio.QM ·2026-10-31 ·Asli Alpman, Nick Bhattacharya, Aaron Solomon, Hunter Elliott
similarity 0.63
Abstract

Recent work has demonstrated agents driving protein design workflows, either through orchestration of specialized tools or direct manipulation of sequences. Yet the fidelity with which agents follow protein design instructions and the factors contributing to their effectiveness remain understudied. We examine agentic antibody design under two settings: when explicit molecular-editing instructions are provided and when agents receive only previously-scored sequences and are prompted to propose improvements. We call the first task-guided and the second black-box design. For the task-guided setting, we curate ten expert-validated affinity-improvement tasks and show that LLM judges closely reproduce programmatic evaluations of instruction following. We then study two augmentations: access to antibody-relevant tools and to previously scored design history. Tools improve instruction following (IF) and sequence space exploration while reducing optimization performance, whereas design history reduces IF but improves optimization performance at the expense of exploration. Finally, we combine taskguided and black-box design within an in silico optimization loop and show that our agentic optimizer performs comparably to an established Bayesian optimization baseline.

0.08

Aptamers as a sandbox for lab-in-the-loop agentic molecular discovery

cs.AI q-bio.BMq-bio.QM ·2026-10-17 ·Zachary Cutts, John Coller, Rachel Chen, Hua Tang, Mathias Bellaiche +7 more
hot direction similarity 0.62
Abstract · Equal leadership (co-senior authors): Pooja Rao and Annalisa Pawlosky. 34 pages, 4 main figures, 1 main table, 3 supplementary figures, 4 su…

Despite breakthroughs in AI-driven molecular generation, existing discovery pipelines operate largely in silico, with wet-lab feedback reserved for validation rather than iterative improvement. Whether large language model (LLM)-based reasoning agents can accelerate de novo discovery by iterating with lab data remains unproven. Here we use protein-binding aptamer design as a sandbox (1-2 week cycles, \$1-\$3 per candidate) to demonstrate a wet lab in a closed loop with AI systems. We tasked agentic pipelines with developing aptamer binders against $α$-thrombin and myoglobin across three design-test-improve cycles ($\sim$1,000 candidates per round; $\sim$4,400 constructs). Statistically significant, bead-corrected on-target hit rates among new candidates rose across rounds from 0.0% in Round 1 to 26.0% in Round 2 and 42.1% in Round 3 on $α$-thrombin (37.1% excluding literature motif descendants), and from 10.2% in Round 1 to 3.7% in Round 2 and 33.5% in Round 3 on myoglobin. Single-clone bead-binding titrations of eight full-length $α$-thrombin candidates confirmed concordance with pooled sequencing enrichment (Pearson $r = 0.90$). In these assays, literature-derived motifs engineered by the agents to reduce off-target reactivity in the pooled screen reached apparent affinities of $K_D = 24.6$--$133$ nM, whereas de novo scaffolds showed low-micromolar binding ($K_D > 1\ μ$M). We also report how our pipelines used myoglobin binding data to exploit the G-quadruplex binder space, diagnose cross-reactivity as on-target specificity dropped from 75.0% to 19.1%, and recover by developing strategies that restored specificity to 72.4%. We demonstrate that empirical lab data is more valuable than existing computational proxies, showing how iterative experimental feedback enables AI agents to diagnose assay artifacts and refine molecular designs across rounds.

0.52

A Modular Agentic Framework for Synthetically Constrained Multi-Objective Hit-to-Lead Optimization

cs.AI cs.LGq-bio.QM ·2026-08-11 ·Kelvin P. Idanwekhai, Enes Kelestemur, Benjamin Strickland, Matthew Hart, Steini Davidsson +4 more
code/data similarity 0.61
Abstract · 22 pages, 9 figures

Hit-to-lead optimization requires iterative design of hit analogs across competing potency, selectivity, physicochemical, pharmacokinetic, safety, and synthetic constraints. We present SABLE (Synthetically-accessible Agentic Bayesian Ligand Exploration), an open-source framework that employs natural-language orchestration to guide chemical structure optimization. SABLE uses an LLM to interpret user-defined goals and route tasks, while specialized tools perform reaction-templated analog enumeration, physicochemical and ADMET property prediction, structure-based affinity scoring, and Bayesian optimization. The resulting workflow is a computational twin of the analytical and prioritization stages of the design-make-test-analyze cycle, providing provenance of each numerical output. Across single, and multi-objective optimization studies, SABLE enriches candidate sets for user-defined computational objectives while evaluating only a subset of the enumerated search space. Its modular architecture allows tools and characterization backends to be replaced by editing a simple config file, without modifying operational logic. SABLE provides an extensible decision-support framework for prioritizing synthetically constrained analogs in early-stage drug discovery.

0.26

Multimodal reasoning for broadly neutralizing antibody discovery from label-free human B cell repertoires across virus families

cs.AI q-bio.QMcs.CEq-bio.CB ·2026-10-02 ·Hantao Lou, Jianqing Zheng, Can Yue, Meihan Zhang, Yuanchao Bao +19 more
similarity 0.60
Abstract

Discovering broadly neutralizing antibodies (bnAbs) from human natural immune repertoires remains a fundamental challenge in immunology, hindered by: the extreme rarity of bnAb, incomplete understanding of their cellular origins across pathogens, and the inability of existing computational tools to generalize across emerging viral threats. Here we present ImmuneAgent, a closed-loop AI system that integrates multimodal reasoning with continual meta-learning and wet-lab feedback to overcome these barriers. Applied to screen the natural BCR repertoires from vaccinated or infected cohorts, the system achieves a ~55% neutralization antibody discovery rate (60 of 110 cloned candidates) and a ~11% bnAb yield (12 of 110), substantially outperforming a state-of-the-art sequence-based neutralization predictor or cofolding models evaluated at the same cloning budget. Five ImmuneAgent-discovered antibodies conferred 100% in vivo protection against lethal influenza challenge, comparable to the clinical-stage therapeutic MEDI8852. The system recovered the cellular and structural determinants of bnAb activity and identified FCRL5+CD27+ atypical memory B cells as a conserved bnAb reservoir and hydrophobic interface enrichment as a cross-viral structural signature, which generalized to unseen antigens, discovering human metapneumovirus (hMPV) cross-neutralizing and human papillomavirus (HPV)-neutralizing antibodies without antigen-specific sorting. These results validate that ImmuneAgent is a generalizable framework for rapid therapeutic antibody discovery against emerging viral threats.

0.20

Revisiting Structure-Based Filtering for AI-Designed Antibodies: Opportunities, Limits, and What Matters

cs.CE ·2026-10-16 ·Langzhang Liang, Juncheng Qian, Xiaojie Ma, Mingxi Zou, Yinghui Xu +2 more
similarity 0.58
Abstract · 29 pages, 4 figures

AI antibody design can generate far more candidates than can be experimentally tested, making post-generation filtering a central bottleneck. We study whether structure-prediction outputs can help prioritize AI-designed antibodies for experimental validation. We evaluate this problem on 4,184 experimentally characterized antibody-antigen pairs, combining newly generated wet-lab measurements with curated affinity data across diverse antigens and assay settings. We introduce two complementary filtering signals: Regional Interaction Contrast (RIC), which captures support for the predicted antibody-antigen interface, and Non-CDR Antibody Confidence (NAC), which measures antibody confidence outside the CDRs. Across AlphaFold 3, Protenix-v2, and ESMFold2, we find a striking difference in what information matters for filtering. Interface evidence is strongest when comparing candidates designed for different antigens, whereas antibody-level reliability is substantially more informative for ranking candidates within the same antigen. In particular, non-CDR antibody confidence consistently outperforms whole-antibody confidence across predictors, revealing an unexpected source of filtering signal beyond the predicted interface. Finally, we examine the information encoded in the predictor outputs themselves. Predicted structures contain substantial but incomplete binding-related signal, revealing both the opportunities and limits of structure-based filtering: better metrics can exploit current predictors more effectively, but their performance ultimately remains constrained by what those predictors can distinguish.

0.32

From Benchmark to Bench: Can Agents Survive Real-World Drug Discovery?

cs.AI ·2026-10-05 ·Pierre Llompart, Levent Guner, Helen Lai, Alessandro Tibo, Yijie Xu
publishedbenchmark similarity 0.58
Abstract

Agentic systems increasingly coordinate molecular-design tools, but it is unclear which layer of the stack limits outcomes on real projects. We developed MAGI, an open modular agent that authors objectives, launches and monitors optimization, interprets structure--activity relationships, and revises its strategy accordingly. MAGI generates molecules either directly through the LLM or by delegating to REINVENT 4, with scoring services interchangeable behind a common contract. We tested it across nine retrospective lead-optimization campaigns from three pharmaceutical companies, replayed under fixed temporal cutoffs. Both routes produced valid structures: LLM proposals stayed closer to local chemistry and reached comparable or higher primary activity in fewer operations, whereas REINVENT explored broader chemical space. Whether a campaign met its objective depended on the predictive models, not on the generation route: attainment followed model accuracy on the chemistry proposed, dropping once that chemistry moved outside the model's applicability domain. Separately, a blinded evaluation asked whether the MAGI's output could pass as expert work: chemists were not able to discriminate agentic proposals from held-out compounds, and judged the SAR reasoning broadly plausible yet incomplete. Together, these results position MAGI as a coordination layer pluggable into existing computational chemistry workflows. The ceiling on real projects, however, remains currently set by scorer applicability rather than by tool orchestration.

0.26

EnzymeRSI: A dual-loop recursive self-improvement system for enzyme design

cs.AI ·2026-11-04 ·Genoria AI Team, Yuejie Hou, Lixiang Yang, Yisi Liu, Weiting Tang +2 more
unusual similarity 0.57
Abstract · 28 pages, 8 figures, 7 tables. Revised abstract, text, tables and figure captions for accuracy following expert review; Figure 4 redrawn. Co…

Enzyme engineering usually optimises which candidates to assay within a fixed model and workflow; when the bottleneck is a mismatched method or a failing workflow, that route is hard to escape. We present EnzymeRSI, a dual-loop system for recursive self-improvement (RSI). The outer loop evolves harness assets without changing model weights; the inner loop develops prediction and selection algorithms under controlled conditions; a cloud laboratory system is specified for closing the physical loop with quality-controlled feedback. The outer loop raised the mean development-set Spearman correlation on ProteinGym by 0.044 across five assays, reaching 0.335 on CD19 and 0.683 on OPSD (rhodopsin); of the two first places, only CD19 was produced by the outer loop itself. In ThermoMPNN self-improvement the inner loop reached a PCC of 0.849, and on TadA-Bench a Spearman correlation of 0.307 in 1.13 h. We examined the system's experimental decision-making in three enzyme systems. For the luciferase RLuc, 10 of the 32 nominated substitutions not pre-specified reached at least twice wild-type activity in a single round. For the cytidine deaminase A3A, a variant selected by a rule that caps loss of unmodified C raised 5mC conversion in the weaker CT context from 11.4% to 46.5% and reversed the substrate preference in both contexts. For the DNA polymerase KOD-E, 189 single-substitution variants defined a landscape on which different objective functions selected divergent next steps from the same parent; one assayed combination reached 31.1 times the parent on a modified substrate. By treating the organisation of research and the development of algorithms as separately scored objects of evolution, and linking a frozen decision record to a physical measurement, this work offers an evolutionary paradigm for moving beyond the blind spots of a fixed method and for autonomous enzyme engineering.

0.30

Nanopath: Fast, Fair, Open Experimentation for Pathology Foundation Models

cs.CV q-bio.TO ·2026-11-04 ·Paul S. Scotti, Hassan Muhammad, Ryan Kim, Nima Ashjaee, Ratna Sagari Grandhi +7 more
publishedbenchmarkcode/data similarity 0.57
Abstract · 17 pages, 2 figures, 10 tables. NeurIPS 2026 workshop: AI at Scale for Clinical Impact: Cancer Pathology Foundation Models

We introduce nanopath, an open-source framework and benchmark for rapidly training and evaluating small-scale pathology foundation models. Using a single H100 GPU, a typical nanopath model trains in a little over an hour on up to one million TCGA pathology tile presentations and evaluates within 25 minutes on a broad suite of tile-level and slide-level tasks. Nanopath enables rapid exploration of research ideas at small scale, so promising training recipes can subsequently be tested with more data and compute. To enable fair comparisons between ideas, we constrain submissions to fixed data and compute budgets while keeping the downstream evaluation protocol fixed. Anyone may clone the codebase, automatically download the data, reproduce or modify existing models, and submit a run to Labless, our public experiment ledger where researchers and AI agents can search through prior attempts. Since its public release in June 2026, nanopath has received 1,269 experiments from 20 contributors. Here, we detail its design and assess how well its rapid evaluation tracks standardized THUNDER, HEST, and PathoBench (CPTAC) benchmarks across six nanopath and 14 reference foundation models. Nanopath's fast evaluation suite strongly tracked these standardized benchmarks, and a few 22M parameter nanopath models even outperformed giant 1.1B parameter models on a subset of downstream tasks. We subsequently discuss how we have since optimized nanopath's evaluation suite to be an even more faithful, quick proxy for external benchmarking. Nanopath provides an accessible testbed for students, researchers, and AI agents to explore pathology foundation modeling through fair, transparent, and directly comparable experiments.

0.39